ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Last update: 4 days ago, 11:04AM

84.69

0.86 (1.03%)

  • 1D 1.03%
  • 5D 0.19%
  • 1M 12.38%
  • 6M 21.77%
  • YTD 28.55%
  • 1Y 11.58%
  • 5Y 59.58%
Previous Close 83.83
Open 83.90
Volume 3,125,391
Avg. Volume (3M) 5,049,212
Market Cap 262,582,976,512
Price / Earnings (TTM) 31.96
Price / Earnings (Forward) 16.31
Price / Sales 4.63
Price / Book 5.80
52 Weeks Range
61.24 (-27%) — 86.57 (2%)
Earnings Date 6 Nov 2025
TTM Dividend Yield 1.85%
Profit Margin 14.14%
Operating Margin (TTM) 27.94%
Diluted EPS (TTM) 2.48
Quarterly Revenue Growth (YOY) 7.20%
Quarterly Earnings Growth (YOY) 33.80%
Total Debt/Equity (MRQ) 77.11%
Current Ratio (MRQ) 0.900
Operating Cash Flow (TTM) 13.09 B
Levered Free Cash Flow (TTM) 9.35 B
Return on Assets (TTM) 8.16%
Return on Equity (TTM) 19.79%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bearish
Drug Manufacturers - General (Global) Bullish Bearish
Stock Astrazeneca PLC Mixed Mixed

AIStockmoo Score

0.8
Analyst Consensus 2.0
Insider Activity NA
Price Volatility -3.0
Technical Moving Averages 0.0
Technical Oscillators 4.0
Average 0.75

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
AZN 263 B 1.85% 31.96 5.80
SNY 120 B 4.60% 16.03 1.49
AMGN 161 B 3.14% 24.45 21.55
GILD 141 B 2.08% 23.78 6.97
GRFS 6 B 1.73% 28.00 1.12
BIIB 21 B - 13.64 1.29

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Institutions 17.13%

No data within this time range.

No data within this time range.

  • 3M
Date Type Details
19 Oct 2025 Announcement DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
18 Oct 2025 Announcement ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
18 Oct 2025 Announcement ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
17 Oct 2025 Announcement IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
17 Oct 2025 Announcement IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
17 Oct 2025 Announcement TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
17 Oct 2025 CNBC Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
15 Oct 2025 Announcement AstraZeneca unveils expanded manufacturing facility in Texas
13 Oct 2025 Announcement AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
10 Oct 2025 CNBC Trump reaches deal with AstraZeneca to lower U.S. drug prices
09 Oct 2025 Announcement AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
09 Oct 2025 Announcement Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
07 Oct 2025 Announcement Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension
06 Oct 2025 Announcement DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02
29 Sep 2025 Announcement ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
26 Sep 2025 Announcement AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
24 Sep 2025 Announcement ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
22 Sep 2025 Announcement SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
18 Sep 2025 Announcement AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
17 Sep 2025 Announcement Advancing Cancer Research Brings New Hope for Patients Worldwide
17 Sep 2025 Announcement SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
07 Sep 2025 Announcement TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
30 Aug 2025 Announcement Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
24 Aug 2025 CNBC Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
15 Aug 2025 Announcement FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
13 Aug 2025 Announcement The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact
07 Aug 2025 CNBC Eli Lilly shares drop after obesity pill shows modest late-stage trial results
05 Aug 2025 Announcement SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
29 Jul 2025 Announcement AstraZeneca results: H1 and Q2 2025
28 Jul 2025 Announcement IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
Show more
TTM Dividend Yield 1.85%
5Y Average Dividend Yield 2.35%
Payout Ratio 62.37%
Expected Next Dividend Payment Mar 2026
Ex Date Announcement Date Payment Date Details
08 Aug 2025 29 Jul 2025 08 Sep 2025 0.515 Cash
21 Feb 2025 06 Feb 2025 24 Mar 2025 1.05 Cash
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Cash
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Cash
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Cash
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Cash
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Cash
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Cash
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Cash
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Cash
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Cash
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Cash
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Cash
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Cash
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Cash
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Cash
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Cash
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Cash
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Cash
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Cash
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Cash
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Cash
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Cash
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Cash
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Cash
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Cash
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Cash
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Cash
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Cash
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Cash
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Cash
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Cash
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Cash
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Cash
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Cash
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Cash
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Cash
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Cash
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Cash
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Cash
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Cash
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Cash
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.57 2 1.85
2024 1.49 2 2.27
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria